Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioCryst (BCRX – Research Report) today. The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, ...

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of “Moderate ...

BioCryst Pharmaceuticals (NASDAQ: BCRX) Q3 2024 Earnings Call Nov 04, 2024, 8:30 a.m. ET Good day and Welcome to the BioCryst ...

BioCryst (BCRX) delivered earnings and revenue surprises of 0% and 2.01%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Good day and Welcome to the BioCryst Third Quarter 2024 Earnings ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on BioCryst (BCRX – Research Report) today and set a price target of $10.00. The ...

Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. Operator Good day and ...

JP Morgan has recently resumed BioCryst Pharmaceuticals Inc (BCRX) stock to Overweight rating, as announced on November 20, 2023, according to Finviz. Earlier, on September 18, 2023, RBC Capital Mkts ...

Good day and Welcome to the BioCryst Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded. I would now ...

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago. These figures are ...